HAE

The Week

Haemonetics (HAE) rose 13.38% this week to close at $118.69, beating the S&P 500 by about 12.23 percentage points (the benchmark gained 1.15%). Trading was subdued early in the week around $104, with a dip to $101.315 on Wednesday. Thursday brought a gap-up open, a spike to $121, and a settle at $119.47 on the day; Friday pared back slightly to $118.69. Average daily volume this week was 1.17m shares, roughly 94% above the 60-day median, indicating stronger participation.

Key Events

Thursday was the main event. On 8 October, Haemonetics said CSL Plasma expects a US rollout of its devices across all centres by the end of 2027. The stock jumped more than 13% that day and hit a 52-week high. Earlier in the week, on 5 October, the company published its Q1 2027 earnings call transcript, which set the fundamental backdrop for the optimism that followed. By Friday, Haemonetics was a fixture in US market-mover lists, with several outlets asking why the stock gained so sharply in a single session.

Analyst Ratings

A total of 11 brokers cover the name: 5 rate it buy, 4 overweight, 2 hold, and none underweight or sell. The consensus rating is buy, with a consensus target of $122.2, implying about 3.0% upside from the latest close. Targets range from $86 to $140, a wide spread that suggests brokers do not agree on the medium-term price path. Haemonetics ranks 10th out of 36 names in its medical supplies industry.

The Week Ahead

The focus next week shifts to US macro data. NFIB small business optimism and existing home sales land on 13 October, followed by several CPI and core CPI prints on 14 October. Any surprise in inflation could shift risk appetite across healthcare names. On the company side, the next earnings report (Q2 2027) is not due until 5 November pre-market, so the CSL Plasma rollout narrative from this week will remain unverified until order and install data arrive.

In Short

Haemonetics put in a high-volume advance this week, catalysed by the CSL Plasma US rollout plan, while the analyst base remains favourably rated. On the other side, the stock trades around 56x P/E and 6.45x P/B, which is not cheap, and the target range shows real dispersion. The latest trading day’s large-lot flow was net positive at $6.09m, with small-lot flow also net positive. The next test is whether next week’s inflation data and the November earnings report can support this week’s optimistic narrative.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.